Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557698244> ?p ?o ?g. }
- W2557698244 abstract "The objective of this analysis was to assess the effects of edoxaban compared with enoxaparin on key coagulation biomarkers and present pooled primary efficacy and safety results from phase 3 STARS E-3 and STARS J-V trials for prevention of venous thromboembolism (VTE) after total knee arthroplasty (TKA) or total hip arthroplasty (THA). In the randomized, double-blind, double-dummy, multicenter, STARS E-3 and STARS J-V trials, patients received edoxaban 30 mg or enoxaparin 2000 IU (20 mg) twice daily for 11 to 14 days. The studies were conducted in Japan and Taiwan; enoxaparin dosing was based on Japanese label recommendations. The primary efficacy endpoint was incidence of VTE; the safety endpoint was major or clinically relevant nonmajor (CRNM) bleeding. Blood samples were taken at presurgical evaluation, pretreatment (postsurgery), predose on day 7, predose on completion of treatment, and at a follow-up examination 25 to 35 days after the last dose of study drug for D-dimer, prothrombin fragment 1 + 2 (F1+2), and soluble fibrin monomer complex (SFMC) measurement. A total of 716 patients enrolled in STARS E-3 and 610 patients enrolled in STARS J-V; 1326 patients overall. This analysis included 657 patients who received edoxaban 30 mg QD and 650 patients who received enoxaparin 20 mg BID. Incidence of VTE was 5.1 and 10.7% for edoxaban and enoxaparin, respectively (P <0.001). Incidence of combined major and CRNM bleeding was 4.6 and 3.7% for edoxaban and enoxaparin, respectively (P = 0.427). On day 7, mean D-dimer (4.4 vs 5.5 μg/mL), F1+2 (363 vs 463 pmol/L), and SFMC (5.7 vs 6.8 μg/mL) were lower in edoxaban-treated patients relative to enoxaparin-treated patients, respectively (P <0.0001 for all). At end of treatment, mean D-dimer (5.4 vs 6.2 μg/mL), F1+2 (292 vs 380 pmol/L), and SFMC (6.2 vs 7.2 μg/mL) were lower in edoxaban-treated patients relative to enoxaparin-treated patients (P <0.0001 for all). Edoxaban was superior to enoxaparin in prevention of VTE following TKA and THA, with comparable rates of bleeding events. Relative to enoxaparin, edoxaban significantly reduced D-dimer, F1+2, and SFMC. Clintrials.gov NCT01181102 and NCT01181167 . Both registered 8/12/2010." @default.
- W2557698244 created "2016-12-08" @default.
- W2557698244 creator A5006900813 @default.
- W2557698244 creator A5033861263 @default.
- W2557698244 creator A5052583987 @default.
- W2557698244 creator A5065667541 @default.
- W2557698244 creator A5076474598 @default.
- W2557698244 creator A5083615429 @default.
- W2557698244 creator A5091666511 @default.
- W2557698244 date "2016-12-01" @default.
- W2557698244 modified "2023-09-26" @default.
- W2557698244 title "Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials" @default.
- W2557698244 cites W1528007237 @default.
- W2557698244 cites W1550111394 @default.
- W2557698244 cites W1974709342 @default.
- W2557698244 cites W2016499071 @default.
- W2557698244 cites W2022932023 @default.
- W2557698244 cites W2030368027 @default.
- W2557698244 cites W2066978830 @default.
- W2557698244 cites W2078568237 @default.
- W2557698244 cites W2096913021 @default.
- W2557698244 cites W2099207046 @default.
- W2557698244 cites W2107205214 @default.
- W2557698244 cites W2110956548 @default.
- W2557698244 cites W2125646842 @default.
- W2557698244 cites W2132129692 @default.
- W2557698244 cites W2148879334 @default.
- W2557698244 cites W2158902152 @default.
- W2557698244 cites W2161023907 @default.
- W2557698244 cites W2167728254 @default.
- W2557698244 cites W2399665981 @default.
- W2557698244 cites W4244303201 @default.
- W2557698244 doi "https://doi.org/10.1186/s12959-016-0121-1" @default.
- W2557698244 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5134224" @default.
- W2557698244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27980462" @default.
- W2557698244 hasPublicationYear "2016" @default.
- W2557698244 type Work @default.
- W2557698244 sameAs 2557698244 @default.
- W2557698244 citedByCount "8" @default.
- W2557698244 countsByYear W25576982442015 @default.
- W2557698244 countsByYear W25576982442018 @default.
- W2557698244 countsByYear W25576982442019 @default.
- W2557698244 countsByYear W25576982442022 @default.
- W2557698244 countsByYear W25576982442023 @default.
- W2557698244 crossrefType "journal-article" @default.
- W2557698244 hasAuthorship W2557698244A5006900813 @default.
- W2557698244 hasAuthorship W2557698244A5033861263 @default.
- W2557698244 hasAuthorship W2557698244A5052583987 @default.
- W2557698244 hasAuthorship W2557698244A5065667541 @default.
- W2557698244 hasAuthorship W2557698244A5076474598 @default.
- W2557698244 hasAuthorship W2557698244A5083615429 @default.
- W2557698244 hasAuthorship W2557698244A5091666511 @default.
- W2557698244 hasBestOaLocation W25576982441 @default.
- W2557698244 hasConcept C120665830 @default.
- W2557698244 hasConcept C121332964 @default.
- W2557698244 hasConcept C126322002 @default.
- W2557698244 hasConcept C141071460 @default.
- W2557698244 hasConcept C203092338 @default.
- W2557698244 hasConcept C2776301958 @default.
- W2557698244 hasConcept C2776884760 @default.
- W2557698244 hasConcept C2777557582 @default.
- W2557698244 hasConcept C2778661090 @default.
- W2557698244 hasConcept C2778825682 @default.
- W2557698244 hasConcept C2779161974 @default.
- W2557698244 hasConcept C2780290652 @default.
- W2557698244 hasConcept C535046627 @default.
- W2557698244 hasConcept C61511704 @default.
- W2557698244 hasConcept C71924100 @default.
- W2557698244 hasConceptScore W2557698244C120665830 @default.
- W2557698244 hasConceptScore W2557698244C121332964 @default.
- W2557698244 hasConceptScore W2557698244C126322002 @default.
- W2557698244 hasConceptScore W2557698244C141071460 @default.
- W2557698244 hasConceptScore W2557698244C203092338 @default.
- W2557698244 hasConceptScore W2557698244C2776301958 @default.
- W2557698244 hasConceptScore W2557698244C2776884760 @default.
- W2557698244 hasConceptScore W2557698244C2777557582 @default.
- W2557698244 hasConceptScore W2557698244C2778661090 @default.
- W2557698244 hasConceptScore W2557698244C2778825682 @default.
- W2557698244 hasConceptScore W2557698244C2779161974 @default.
- W2557698244 hasConceptScore W2557698244C2780290652 @default.
- W2557698244 hasConceptScore W2557698244C535046627 @default.
- W2557698244 hasConceptScore W2557698244C61511704 @default.
- W2557698244 hasConceptScore W2557698244C71924100 @default.
- W2557698244 hasFunder F4320334790 @default.
- W2557698244 hasIssue "1" @default.
- W2557698244 hasLocation W25576982441 @default.
- W2557698244 hasLocation W25576982442 @default.
- W2557698244 hasLocation W25576982443 @default.
- W2557698244 hasLocation W25576982444 @default.
- W2557698244 hasOpenAccess W2557698244 @default.
- W2557698244 hasPrimaryLocation W25576982441 @default.
- W2557698244 hasRelatedWork W1985700561 @default.
- W2557698244 hasRelatedWork W2341853134 @default.
- W2557698244 hasRelatedWork W2402571166 @default.
- W2557698244 hasRelatedWork W2557698244 @default.
- W2557698244 hasRelatedWork W2743995415 @default.
- W2557698244 hasRelatedWork W2912325088 @default.
- W2557698244 hasRelatedWork W2979415664 @default.
- W2557698244 hasRelatedWork W2999402470 @default.
- W2557698244 hasRelatedWork W3142662150 @default.